Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients

Ferguson, James M., Wesnes, Keith A., Schwartz, Gerri E. · 2003 · International Clinical Psychopharmacology

Abstract

Impaired cognitive functioning is often associated with major depressive disorder (MDD). Moreover, a number of agents used to treat MDD are known to have negative effects on cognitive functioning. We report an assessment of the effects of the selective norepinephrine reuptake inhibitor reboxetine, the selective serotonin reuptake inhibitor paroxetine, and placebo on a variety of measures of cognitive functioning in patients with MDD. Cognitive functioning in 74 adult patients (aged 18-65 years) with a confirmed diagnosis of MDD (DSM-IV) was assessed as part of two identical, randomized, double-blind, placebo- and active-treatment-controlled, fixed/flexible dose comparisons of 8 weeks of treatment with reboxetine (8-10 mg/day), paroxetine (20-40 mg/day) and placebo. Cognitive function was assessed at baseline, day 14 and day 56 using a selection of tasks from the Cognitive Drug Research computerized assessment system, including Simple Reaction Time, Digit Vigilance, Choice Reaction Time, Numeric Working Memory, Word Recognition and Critical Flicker Frequency. The results in the 74 patients (reboxetine n = 25, paroxetine n = 23, placebo n = 26) showed that reboxetine significantly improved the ability to sustain attention at day 56 compared with baseline (P = 0.023). In addition, patients who received reboxetine experienced significant improvements in their speed of cognitive functioning when tested at day 56 compared to baseline (P = 0.024). No significant changes or trends in this direction were seen among patients who received either placebo or paroxetine. The results of the present study provide objective data to support the possibility that reboxetine favourably affects cognitive processes in depressed patients.

Overview

Integrity signals

Registry

Crossref · 10.1097/00004850-200301000-00002

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 21 references

Research works printed but not linked: 8

  1. Dubini, 1997b, J Psychopharmacol, 11, S17???S23
  2. Friedman, 1999, Biol Psychiatry, 46, 1243???1252
  3. Kleinbloesem, 1996, Clin Pharmocol Ther, 59, 675???685
  4. Montgomery, 1997, J Psychopharmacol, 11, S9???S15
  5. O??Neill, 1995, Eur J Clin Pharmacol, 48, 447???453
  6. Wesnes, 1989, Br J Clin Pharmacol, 27, 647???648
  7. Wesnes, 1997, Br J Surgery, 84, 493???495, 10.1002/bjs.1800840416 · doi:10.1002/bjs.1800840416
  8. Wesnes, 1996, J Psychopharmacol, 10, A51

Cited by

See all 114

Metadata

Authors
Ferguson, J. M., Wesnes, K. A., & Schwartz, G. E.
Affiliations
  • University of Utah (US)
  • Columbia University (US)
Corresponding author
Ferguson, James M.
Venue
International Clinical Psychopharmacology
Published
2003-01
Volume
18
Issue
1
Pages
9-14
ISSN
0268-1315 (ISSN-L)
OpenAlex
W1982842917
Cited by
112
References
21
Citations by year
2024: 1 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 5 · 2018: 6 · 2017: 5 · 2016: 13 · 2015: 5 · 2014: 10 · 2013: 10 · 2012: 3
FWCI
3.95
Type
journal article
Language
en
Open access
closed
Locations
  • International Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
reboxetine, paroxetine, major depressive disorder, cognitive function, attention, reaction time, working memory, norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, antidepressant side effects, cognitive impairment in depression
MeSH terms
Reboxetine, Adolescent, Adult, Aged, Antidepressive Agents, Cognition Disorders, Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Morpholines, Placebos, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Paroxetine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. https://app.cochat.ai/papers/10.1097/00004850-200301000-00002
The paper
Ferguson, J. M., Wesnes, K. A., & Schwartz, G. E. (2003). Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200301000-00002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.